Clinical Trials

Adding ovarian suppression to tamoxifen reduced recurrence for some premenopausal breast cancer

By

Among premenopausal women with early stage, HR-positive breast cancer, the addition of ovarian suppression to tamoxifen reduced breast cancer recurrence.

Tamoxifen found to lower breast cancer rates among high-risk women in trial

By

The International Breast Cancer Intervention Study-I (IBIS-I) trial found that tamoxifen significantly decreased the incidence of all breast cancers, according to data presented at the 2014 San Antonio Breast Cancer Symposium.

Pembrolizumab safe, and even effective in some patients, for triple-negative breast cancer

By

Pembrolizumab was well tolerated and yielded durable responses in patients with metastatic triple-negative breast cancer, according to recent trial data.

Rociletinib produces response in treatment-resistant advanced non-small cell lung cancer (NSCLC)

By

A new drug that targets common cancer-causing genetic mutations in patients with non-small cell lung cancer (NSCLC), and a type of the mutation responsible for treatment resistance, has shown promising results in a phase I/II clinical trial.

IDH1 mutation inhibitor first to demonstrate anticancer activity

By

The first drug designed to inhibit the cancer-causing activity of a mutated enzyme known as isocitrate dehydrogenase (IDH) 1 has shown clinical activity in patients with advanced acute myeloid leukemia (AML) with the IDH1 mutation.

Galeterone active in one form of castration-resistant prostate cancer

By

The anticancer drug galeterone has proved successful in lowering prostate-specific antigen levels in men with castration-resistant prostate cancer (CRPC).

Researchers identify biological indicator of response to new ovarian cancer drug

By

A method to determine which patients with ovarian cancer are more likely to respond well to the new anticancer drug rucaparib has been discovered.

Certain cases of advanced colorectal cancer respond better to three-drug regimen

By

Previously, patients with advanced colorectal cancer driven by a mutated version of the BRAF gene have had limited treatment options, but results from a multicenter clinical trial suggest a new option.

Response to new drug in patients with lymphomas and advanced solid tumors

Patients with B-cell non-Hodgkin lymphomas and advanced solid tumors have responded to a new drug that is being tested for the first time in humans in a phase I clinical trial.

Latina patients with breast cancer more given more information more likely to enter clinical trials

Latina patients with breast cancer more given more information more likely to enter clinical trials

Latina patients with breast cancer had much more awareness of clinical trials versus women who received the typical information.

Personalized cellular therapy leads to complete remission in acute lymphoblastic leukemia

Personalized cellular therapy leads to complete remission in acute lymphoblastic leukemia

By

An investigational personalized cellular therapy was found to have achieved remission in some 90% of children and adults with acute lymphoblastic leukemia (ALL) tested.

Drug targeting glioblastoma to begin clinical trial

By

A new drug breakthrough could extend the life of people living with glioblastoma, the most aggressive type of brain cancer.

New drug for multiple myeloma to begin clinical trial

New drug for multiple myeloma to begin clinical trial

By

A new drug in development, known as DTP3, has killed myeloma cells in laboratory tests in human cells and mice.

Achieving clinical trial participation through cooperative networks

Achieving clinical trial participation through cooperative networks

By

Clinical trials could benefit from a greater number of participants with a dedicated cooperative network to support rural community cancer centers.

Prior cancer exclusion criteria may stymie potential of lung cancer clinical trials

By

A history of prior cancer can exclude many individuals from participation in clinical trails related to lung cancer, even when the prior cancer is unlikely to interfere with treatment outcomes.

PD-L1 a possible immunotherapy target in mesothelioma

By

Approximately one fifth of patients with malignant pleural mesothelioma have cancer cells that express a protein called programmed cell-death ligand 1 (PD-L1), which has been associated with poorer outcomes.

Improved response rate and survival with dabrafenib plus trametinib versus vemurafenib alone

Targeting BRAF V600E/K mutation-positive melanoma with dabrafenib in combination with trametinib achieves longer overall survival and impoved response rates, compared to treatment with vemurafenib alone.

Dabrafenib hitting the target in subset of patients with non-small cell lung cancer

By

The BRAF inhibitor dabrafenib has significant antitumor activity in patients with advanced BRAF V600E mutant non-small cell lung cancer (NSCLC) whose disease has progressed after chemotherapy, according to phase II data.

Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization (ALTTO) study confirms use of trastuzumab for HER2-positive breast cancer

By

The use of trastuzumab (Herceptin) as the standard-of-care treatment for HER2-positive breast cancer has been supported by the Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization (ALTTO) study.

Once-weekly breast radiation regimen improves on current treatment

By

An experimental regimen of once-weekly breast irradiation after lumpectomy provides more convenience to patients at less expense, and results in better completion rates of prescribed radiation treatment.

Clinical trial results of nintedanib for HER2-negative breast cancer are promising

By

The experimental drug nintedanib, in combination with standard paclitaxel chemotherapy, caused a total remission of tumors in half of patients with early stage HER2-negative breast cancer.

Prostate Cancer Prevention Trial identifies men most likely to undergo biopsy

By

Healthy men participating in the Prostate Cancer Prevention Trial who actively participate in all trial steps are most likely to undergo a biopsy at the end of the trial, according to recent research.

Everolimus does not improve overall survival of advanced liver cancer

By

Despite strong preclinical data, the drug everolimus failed to improve overall survival in patients with advanced liver cancer, compared to placebo, according to a study.

Resistant sarcomas slowed by new therapeutic combination

By

A new therapeutic combination to combat resistant sarcomas has shown promise in a trial.

US Food and Drug Administration fast-tracks novel leukemia therapy

US Food and Drug Administration fast-tracks novel leukemia therapy

An experimental immunotherapy agent was placed on the US Food and Drug Administration's fast track to market approval after overwhelmingly positive results were seen in patients with leukemia. In early trials, 89% of patients who received the personalized immunotherapy known as CTL019 saw their cancers disappear.

Surgical Biopsy Safe for Some Patients With Late-Stage Lung Cancer

Surgical Biopsy Safe for Some Patients With Late-Stage Lung Cancer

Surgical biopsy is safe for certain late-stage lung cancer patients and could improve their chances of getting treated with newer types of drugs that target cancer-related genetic mutations.

Direct injection treatment of pancreatic cancer shows encouraging results

Direct injection treatment of pancreatic cancer shows encouraging results

Results of a phase I clinical trial of a vaccine therapy for pancreatic cancer indicate the treatment is well tolerated; in addition, it suggests that the vaccine stabilizes the disease for a period of time.

Study demonstrates improved diagnosis and outcomes with LDCT

By

A study using a 5-year LDCT screening protocol showed good adherence and patient survival outcomes in persons at high risk of developing lung cancer.

Developing an innovative online cancer information center

Developing an innovative online cancer information center

By

An increasingly complex environment for cancer care and research highlights the need to streamline access to cancer information, especially clinical trials.

Phase 1 trials begin for first-in-class anticancer drug

By

Clinical trials have begun for PFK-158, a small-molecule therapeutic candidate that inactivates a novel cancer metabolism target never before examined in human clinical trials.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs